Back to top

immuno-therapy: Archive

Zacks Equity Research

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

TEVANegative Net Change BAYRYNegative Net Change AGENPositive Net Change IMCRPositive Net Change